Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
Clinics
;
68(3): 339-343, 2013. graf, tab
Article
Dans Anglais
| LILACS
| ID: lil-671424
ABSTRACT
OBJECTIVES:
To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.METHODS:
A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival.RESULTS:
A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02).CONCLUSIONS:
These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Myélofibrose primitive
Type d'étude:
Etude d'étiologie
/
Études d'évaluation
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adulte
/
Adulte très âgé
/
Aged80
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Clinics
Thème du journal:
Médicament
Année:
2013
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Universidade Estadual de Campinas/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS